정규장
로그인 회원가입
ZTS
Zoetis Inc
7월 27일 1:46 PM ET (한국 7/28 02:46)
$75.35
+0.78 ▲ +1.05%

조에티스(ZTS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$31.6B
미드캡
P/E
12.5
저평가 구간
배당수익률
2.84%
52주 위치
4%
저점 +5% · 고점 -53%
애널리스트
매수
B
Fundamental health
vs. Drug Manufacturers - Specialty & Generic
수익성 ⓘ
Top 7%
성장 ⓘ
Top 46%
밸류에이션 ⓘ
Top 54%
재무 안정 ⓘ
Top 28%
💰 Is this stock pricier than usual right now? ⓘ
Compared to this company's own recent 5년 (not other companies).
💎 Very cheap
Cheap
Typical
Pricey
Very pricey
Simply put — what you pay today to own $1 of this company's yearly earnings is 12원. Over the past 5년, it usually traded around 35원. One of the cheapest stretches of the past 5년.
Pricy doesn't mean bad — it means expectations are already baked in.
Index ⓘ S&P 500P/E ⓘ 12.48EPS (ttm) ⓘ 6.04Insider Own ⓘ 0.57%Shs Outstand ⓘ 420.4MPerf Week ⓘ -1.58%
Market Cap ⓘ 31.59BForward P/E ⓘ 10.23EPS next Y ⓘ 7.09%Insider Trans ⓘ -0.35%Shs Float ⓘ 416.8MPerf Month ⓘ -3.61%
Enterprise Value ⓘ 38.89BPEG ⓘ 1.36EPS next Q ⓘ 1.85Inst Own ⓘ 99.85%Short Float ⓘ 3.82%Perf Quarter ⓘ -35.08%
Income ⓘ 2.64BP/S ⓘ 3.32EPS this Y ⓘ 7.31%Inst Trans ⓘ -0.85%Short Ratio ⓘ 2.14Perf Half Y ⓘ -39.43%
Sales ⓘ 9.51BP/B ⓘ 9.8EPS next 5Y ⓘ 7.54%ROA ⓘ 18.07%Short Interest ⓘ 15.92MPerf YTD ⓘ -40.11%
Book/sh ⓘ 7.69P/C ⓘ 16.27EPS past 3/5Y ⓘ 10.25% 11.96%ROE ⓘ 67.01%52W High ⓘ -53.05% ($160.48)Perf Year ⓘ -50.69%
Cash/sh ⓘ 4.63P/FCF ⓘ 14.79Sales past 3/5Y ⓘ 5.42% 7.24%ROIC ⓘ 21.19%52W Low ⓘ 5.43% ($71.47)Perf 3Y ⓘ -59.4%
Dividend Est. ⓘ $2.14 (2.84%)EV/EBITDA ⓘ 9.58EPS Y/Y TTM ⓘ 8.35%Gross Margin ⓘ 70.43%Volatility(W/M) ⓘ 2.7% 2.91%Perf 5Y ⓘ -62.99%
Dividend TTM ⓘ 2.09EV/Sales ⓘ 4.09Sales Y/Y TTM ⓘ 2.4%Oper. Margin ⓘ 37.57%ATR (14) ⓘ 2.34Perf 10Y ⓘ 49.92%
Dividend Ex-Date ⓘ 2026/7/20Quick Ratio ⓘ 1.91EPS Q/Q ⓘ 1.02%Profit Margin ⓘ 27.79%RSI (14) ⓘ 45.26Recom ⓘ 1.95
Dividend Gr. 3/5Y ⓘ 14.57% 19.02%Current Ratio ⓘ 3.15Sales Q/Q ⓘ 1.89%SMA20 ⓘ 0.53% ($74.95)Beta ⓘ 0.73Target Price ⓘ $107.5
Payout ⓘ 33.71%Debt/Eq ⓘ 2.86Earnings ⓘ 2026/8/6SMA50 ⓘ -2.25% ($77.08)Rel Volume ⓘ 0.68Prev Close ⓘ $74.57
Employees ⓘ 14500LT Debt/Eq ⓘ 2.86EPS/Sales Surpr. ⓘ -4.6% -1.71%SMA200 ⓘ -32.78% ($112.09)Avg Volume(3M) ⓘ 7.43MPrice ⓘ $75.35
IPO ⓘ 2013/2/1Option/Short ⓘ Yes/YesTrades ⓘ 33364Volume ⓘ 5,089,813Change ⓘ 1.05%
Quarterly earnings trend SEC filings · USD
24.6
24.9
24.12*
25.3
25.6
25.9
25.12*
26.3
Revenue Net income 최근 분기: 매출 $2.3B (YoY +3%) · 순이익 $601M (YoY 0%)
* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Zoetis Inc (ZTS) Investment Analysis

What kind of company is Zoetis Inc?

조에티스(ZTS) 배당주
Healthcare · Drug Manufacturers - Specialty & Generic
Top 446 by Market Cap — Large-Cap

🐾 Zoetis (ZTS) is a global leader in the animal pharmaceuticals, vaccines, and diagnostics market, with a broad product portfolio spanning both companion animals and livestock. Since becoming an independent company from a global pharmaceutical company in 2013, it has maintained a top global position in the single category of animal healthcare.

Learn more about Zoetis Inc →
Market Cap
$31.6B
Approx. KRW 43.3 trillion
⚖️ 11% of Samsung Electronics
Market Cap Rank446
Employees14,500people
IPO2013/02/01
Current Price$75.35 ≈ 103,229원
📌 S&P 500 · NYSE · USA

Key Events

⏰ Upcoming events
🔔 Earnings release D-10
8월 6일 (목) · 장 시작 전
예상 EPS $1.85
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🎯 Ex-div 2026년 7월 20일 (월) 주당 $0.53
🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS -4.6% 매출 -1.7%
🎯 Ex-div 2026년 4월 20일 (월)
🔔 Earnings release 2026년 2월 12일 (목) · 장 시작 전

Is it profitable?

Solid company — profitability & finances both healthy
Strong earnings and excellent financial health
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
37.6%
✓ 우수
My positionTop 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median -7.1% · Top tier
💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수
Net Margin
Share of revenue left after taxes and interest are paid
27.8%
✓ 우수
My positionTop 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median -9.3% · Top tier
💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
70.4%
✓ 우수
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 52.5% · Top 21%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
67.0%
✓ 우수
My positionTop 5%
Low range Average High range
Healthcare 대형주 Median 11.9% · Top tier
💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)
ROA
Annual earnings relative to total company assets
18.1%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 대형주 Median 5.1% · Top 8%
💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수
ROIC
Return generated per dollar invested in the business
21.2%
✓ 우수
My positionTop 25%
Low range Average High range
Healthcare 대형주 Median 7.4% · Top 12%
💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
2.86
✓ Very high debt
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 0.36
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
3.15
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
1.91
✓ 양호
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$107.50
현재가 대비 +42.7%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
예상 PER (Forward)
10.23배
💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인
PEG (성장 반영 밸류)
1.36
적정
💡 PEG 1~1.5 — 성장 대비 합리적
내년 EPS 예상 성장률
+7.1%
💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상
5년 EPS 예상 연평균
+7.5%
💡 장기 성장 전망. 15% 이상이면 고성장 기업
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance
Mixed beats and misses
1
예상 상회
0
예상 부합
1
예상 하회
50%
상회 비율
+0.1%
평균 서프라이즈
2026.05.07
하회
실적 $1.53 · 예상 $1.62 -5.3%
2026.02.12
상회
실적 $1.48 · 예상 $1.40 +5.5%
💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
🔮 How much will it grow? (analyst forecasts)
This Year's EPS Outlook
Projected EPS growth rate for this year
+7.3%
양호
My positionMid-range
Low range Average High range
배당주 대형주 Median 5.5% · Top 44%
Next Year's EPS Outlook
Projected EPS growth rate for next year (analyst consensus)
+7.1%
평균
My positionMid-range
Low range Average High range
배당주 대형주 Median 7.3% · Bottom 49%
5-Year EPS CAGR Outlook
Projected average annual EPS growth over the next 5 years
+7.5%
양호
My positionMid-range
Low range Average High range
배당주 대형주 Median 6.7% · Top 41%
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+10.3%
양호
My positionMid-range
Low range Average High range
배당주 대형주 Median 4.1% · Top 33%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+12.0%
양호
My positionMid-range
Low range Average High range
배당주 대형주 Median 6.3% · Top 31%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+7.2%
양호
My positionMid-range
Low range Average High range
배당주 대형주 Median 6.7% · Top 45%
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+1.9%
부진
My positionBottom 25%
Low range Average High range
배당주 대형주 Median 5.9% · Bottom 25%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -131%p below the market
ZTS -63.0% · S&P 500 +68.0%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-130.9%p
Significantly behind the market
vs Health Care (XLV)
-86.6%p
Significantly behind the sector average
1-year basis
vs S&P 500
-67.2%p
Significantly behind the market
vs Health Care (XLV)
-70.4%p
Significantly behind the sector average
Rank among peers
1-year return Bottom 10% Based on 10 peers
Current position within 52-week range
Low (-5.4%p) High (-53.0%p)
Current price is 5.4% above the 52-week low and 53.0% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-45.2%
Annualized volatility
46.4%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-24
Uptrend zone

Current price $75.35 above the midline ($74.95). Normal upward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-24
Neutral zone — weak trend

MACD -1.154 · Signal -1.526 · Hist 0.372. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-24
Bearish zone

RSI 45.3 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 42.2.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Earnings·Vs. Cash Flow, Pricey on Vs. Assets, In line with peers on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
💵 Vs. Earnings Cheap
🏢 Vs. Assets Pricey
🧾 Vs. Sales Mid-range
💧 Vs. Cash Flow Cheap
💵 Vs. Earnings
PER Price-to-Earnings Ratio
How expensive the price is vs. earnings — lower is cheaper
12.48x
✓ Very cheap
My positionTop 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic median 20.36x · Top 17% — relatively cheap within the industry
💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)
💵 Vs. Earnings
Forward PER Forward Price-to-Earnings Ratio
PER using next year's estimated earnings — reflects growth
10.23x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic median 14.70x · Around the industry average
💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
9.80x
✓ Pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic median 1.55x · Bottom 12% — expensive within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.32x
✓ Fair
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic median 2.13x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
9.58x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic median 10.57x · Around the industry average
💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
14.79x
✓ Cheap
My positionMid-range
Low range Average High range
Drug Manufacturers - Specialty & Generic median 18.10x · Around the industry average
💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)
Analyst target price (reference)
$107.50 vs. current price +42.7%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic

Who owns it?

Ownership flow shows some pressure
Insider modest net selling -0.3% · Institutional modest net selling -0.8% · Short interest light 3.8%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-0.3%
Insiders net selling
🏦 Institutions (funds & investors)
-0.8%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 99.8%
Institution-led, stable structure
Healthcare 대형주 Median 91.9%
🧑‍💼 Insiders 0.6%
Low, common among large-caps
Healthcare 대형주 Median 0.8%
👤 Retail investors (estimated) 0.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
3.8%
Low — limited short-side pressure
Healthcare 대형주 Median 3.6%
Past 90 days Little change
Short interest days to cover
2.1 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 420.4M주
Float (tradable shares) 416.8M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding ZTS

ETFs with the highest weightings · 10 total shown
PAWZ
PAWZ
ProShares Pet Care ETF
9.83%
$33M
MOO
MOO
VanEck Agribusiness ETF
6.88%
$983M
IHE
IHE
iShares U.S. Pharmaceuticals ETF
4.52%
$1.6B
GKAT
GKAT
Scharf Global Opportunity ETF
4.16%
$160M
BEEZ
BEEZ
Honeytree U.S. Equity ETF
3.84%
$6M
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당주 — 연 2.84% 배당
5년 배당 성장률 19.02%
Dividend Yield
2.84%
Industry average 1.25%
Dividend Per Share
$2.14
Annualized
Payout Ratio
34%
Share of net income paid as dividends
5-Year Growth
19.0%
Annualized dividend growth
🏆 12년 연속 배당 증가
📅 지급월 1월 · 4월 · 10월
📊 총 이력 2013~2026 (53건)
연도별 배당 총액 추이
주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.
$0.38 +14.5%
2016
$0.42 +10.5%
2017
$0.50 +20.0%
2018
$0.66 +30.2%
2019
$0.80 +22.0%
2020
$1.00 +25.0%
2021
$1.30 +30.0%
2022
$1.50 +15.4%
2023
$1.73 +15.2%
2024
$2.00 +15.7%
2025
$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소
최근 배당 이력 총 53건
아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.
배당락일
주당 금액
지급일
당시 수익률
2026-04-20
$0.530
—
2.09%
2026-01-20
$0.530
—
2.05%
2025-10-31
$0.500
—
1.69%
2025-07-18
$0.500
—
1.59%
2025-04-21
$0.500
—
1.27%
2025-01-21
$0.500
—
1.07%
2024-10-31
$0.432
—
0.97%
2024-07-18
$0.432
—
1.14%
2024-04-18
$0.432
—
1.30%
2024-01-18
$0.432
—
1.01%
2023-10-31
$0.375
—
1.16%
2023-07-20
$0.375
—
1.03%
2023-04-20
$0.375
—
0.99%
2023-01-19
$0.375
—
1.03%
2022-10-31
$0.325
—
0.86%
2022-07-20
$0.325
—
0.84%
2022-04-20
$0.325
—
0.75%
2022-01-19
$0.325
—
0.66%
2021-10-28
$0.250
—
0.47%
2021-07-20
$0.250
—
0.47%
2021-04-20
$0.250
—
0.53%
2021-01-19
$0.250
—
0.52%
2020-10-20
$0.200
—
0.60%
2020-07-16
$0.200
—
0.65%
2020-04-16
$0.200
—
0.70%
2020-01-16
$0.200
—
0.61%
2019-10-21
$0.164
—
0.62%
2019-07-18
$0.164
—
0.65%
2019-04-17
$0.164
—
0.72%
2019-01-17
$0.164
—
0.79%
2018-11-19
$0.126
—
0.56%
2018-07-19
$0.126
—
0.57%
2018-04-19
$0.126
—
0.54%
2018-01-18
$0.126
—
0.72%
2017-11-08
$0.105
—
0.60%
2017-06-13
$0.105
—
0.82%
2017-04-04
$0.105
—
0.94%
2017-01-18
$0.105
—
0.91%
2016-11-01
$0.095
—
0.98%
2016-06-28
$0.095
—
0.97%
2016-04-05
$0.095
—
0.96%
2016-01-19
$0.095
—
0.99%
2015-11-03
$0.083
—
0.87%
2015-08-11
$0.083
—
0.82%
2015-04-07
$0.083
—
0.82%
2015-01-20
$0.083
—
0.85%
2014-11-03
$0.072
—
0.76%
2014-08-18
$0.072
—
0.83%
2014-04-24
$0.072
—
1.13%
2014-01-28
$0.072
—
0.85%
2013-10-30
$0.065
—
0.61%
2013-07-30
$0.065
—
0.43%
2013-04-29
$0.065
—
0.20%
* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.
💰 내가 100만원 투자한다면
연간 배당금 (세후) 2.4만원
5년 누적 (세후) 17.6만원
* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 19.02% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
ZTS This Stock
$31.6B12.5 ▲9.8 ▼67.01% ▲2.84% ▲+1.1%
LLY
$1.13T43.0 ▼36.2 ▼107.64% ▲0.58% ▼+0.9%
JNJ
$634.1B30.5 ▼7.5 ▼25.74% ▲2.04% ▲+1.6%
ABBV
$458.2B127.9 ▼- 15221.82% ▲2.65% ▲+0.9%
UNH
$382.1B27.1 ▼3.9 ▼12.49% ▲2.15% ▲-0.7%
MRK
$323.7B36.9 ▼7.1 ▼18.97% ▲2.49% ▲+0.5%
Sector Avg-25.82.7-48.83%1.25%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
→

Related News & Content

📖 Company overview
조에티스(ZTS) 뭐하는 회사일까? - 주가 전망·실적·시총·관련주·본사 총정리
조에티스 ZTS 주가·실적·전망·시총·관련주·배당·매출·본사 핵심 정리. 반려동물·가축 의약품과 백신·진단을 공급하는 글로벌 동물 헬스케어 선도 기업으로 반려동물 인간화 트렌드 기반의 시장 확장과 신약 출시 사이클이 핵심 변수입니다.
📚 Related Investment Guides
2026년 미국 배당귀족(Dividend Aristocrats) 완전 가이드
S&P 500 소속, 25년 이상 연속 배당 인상한 배당귀족주 69개 전체 리스트. 섹터별 분포, 배당수익률 순위, NOBL ETF 비교까지 한눈에.
미국주식 세금 총정리 2026 — 초보자를 위한 계산법과 절세 전략
2026년 미국주식 세금 총정리. 양도소득세 22% 계산법, 배당세 15% 원천징수, 손익통산, 절세 전략까지. 실제 금액 시뮬레이션과 세금 계산기로 내 세금을 직접 확인해보세요.

FAQ

What kind of company is 조에티스(ZTS)?

조에티스(ZTS) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of ZTS?

The market cap of ZTS is approximately $31.6B, ranking 446 within its sector.

Does ZTS pay dividends?

ZTS has a dividend yield of approximately 2.84%, with an annual dividend of $2.14.

What is the P/E ratio of ZTS?

ZTS has a P/E ratio of approximately 12.5x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for ZTS?

ZTS has recorded a 52-week high of $160.48 and a low of $71.47.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.